TGFB1 and systemic sclerosis: Based on preclinical evidence showing that nintedanib was able to inhibit the TGFβ-induced myofibroblast differentiation in preclinical models of SSc [77] and following the success of nintedanib in IPF trials, two large studies evaluating its efficacy on lung involvement in SSc (SSc-ILD) and in other fibrotic lung diseases with a progressive phenotype (PF-ILD) were conducted in recent years.